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The neurobiology of treatment-resistant schizophrenia: paths
to antipsychotic resistance and a roadmap for future research
Steven G. Potkin1, John M. Kane2,3,4, Christoph U. Correll2,3,4,5, Jean-Pierre Lindenmayer6, Ofer Agid7, Stephen R. Marder 8,9,
Mark Olfson10 and Oliver D. Howes11,12*
Treatment-resistant schizophrenia (TRS), the persistence of positive symptoms despite ≥2 trials of adequate dose and duration of
antipsychotic medication with documented adherence, is a serious clinical problem with heterogeneous presentations. TRS can
vary in its onset (at the first episode of psychosis or upon relapse), in its severity, and in the response to subsequent therapeutic
interventions (i.e., clozapine, electroconvulsive therapy). The heterogeneity of TRS indicates that the underlying neurobiology of TRS
may differ not only from treatment-responsive schizophrenia but also among patients with TRS. Several hypotheses have been
proposed for the neurobiological mechanisms underlying TRS, including dopamine supersensitivity, hyperdopaminergic and
normodopaminergic subtypes, glutamate dysregulation, inflammation and oxidative stress, and serotonin dysregulation. Research
supporting these hypotheses is limited in part by variations in the criteria used to define TRS, as well as by the biological and clinical
heterogeneity of TRS. Clinical trial designs for new treatments should be informed by this heterogeneity, and further clinical
research is needed to more clearly understand the underlying neurobiology of TRS and to optimize treatment for patients with TRS.
npj Schizophrenia             (2020) 6:1 ; https://doi.org/10.1038/s41537-019-0090-z
INTRODUCTION
Treatment-resistant schizophrenia (TRS) has been defined as the
persistence of symptoms despite ≥2 trials of antipsychotic
medications of adequate dose and duration with documented
adherence.1,2 TRS occurs in up to 34% of patients with
schizophrenia.3–5 Although persistent symptoms may be negative
or cognitive,1 persistence of positive symptoms is generally one of
the defining features of TRS.6 However, the failure of serial
antipsychotic medication trials is not sufficient to define TRS, as
other potential causes of persistent symptoms need to be
excluded as well (Table 1). A typical clinical pathway to identifying
patients with TRS is shown in Fig. 1.
TRS may present from the first episode of psychosis3,4,7 or may
develop later in the disease progression. Later onset of treatment
resistance may be preceded by relapses,8–10 which in part may
result from medication nonadherence or discontinuation.2 How-
ever, it is critical to differentiate true TRS from pseudo-resistance
(i.e., when a patient appears resistant, but treatment is inadequate
rather than ineffective).8,11 TRS results from lack of response to
adequate exposure to medication with no confounding factors
(Table 1), whereas pseudo-resistance may occur as a result of
medication nonadherence, insufficient plasma levels of a medica-
tion, inadequate dosage or duration of treatment, misdiagnosis,
adverse events of a treatment masking a response, or the presence
of confounding psychiatric or medical comorbidities.8,11,12
Outcomes for patients with treatment resistance may be
improved if identification of TRS occurs earlier in the course of
disease rather than after a long duration of untreated psycho-
sis.13,14 Early identification of TRS may allow for early introduction
of clozapine, the only approved antipsychotic for TRS.12,15 There is
some evidence suggesting that a trial of clozapine may be
warranted after even one failure of a non-clozapine antipsychotic
course of treatment,16–18 although this requires further research.
Up to 60% of patients with treatment resistance will not respond
even to clozapine.6,19 Although a wide variety of medication
augmentation strategies have been tried, there is a lack of strong
evidence regarding the efficacy of such strategies; thus, patients
with TRS may have limited treatment options.20,21 Electroconvul-
sive therapy (ECT) was found to be helpful for some patients with
clozapine-resistant schizophrenia.22,23
There may be underlying biological differences between
patients with TRS and patients with treatment-responsive schizo-
phrenia.24 Current hypotheses for the biological basis of TRS focus
on differences in the functioning of dopaminergic pathways (i.e.,
supersensitivity or hyper-, normo-, or hypodopaminergic schizo-
phrenia) or changes in glutamate or other neurotransmitter
pathways. These theories are not mutually exclusive, with several
pathways converging and possibly contributing to the neurobiol-
ogy of TRS. Elucidating the underlying pathophysiology of TRS
may aid in better treatment selection and inform development of
future treatments.8,25 Furthermore, additional research identifying
biomarkers of clozapine resistance or response is needed, as well
as new treatments for clozapine-resistant schizophrenia.
The goal of this review is to examine advances in our
understanding of the underlying neurobiology of TRS as it relates
to positive symptoms, that is, symptoms that were not responsive
to antipsychotic treatment from illness onset or that were
previously, but are no longer, responsive to antipsychotic
treatment. Treatment-resistant negative and cognitive symptoms
are of great clinical relevance, but the underlying pathophysiology
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mechanisms are not well understood and more research is needed
to identify appropriate treatments for these domains; negative and
cognitive symptoms, therefore, are not discussed further in this
review. This review examines potential neurophysiological and
molecular mechanisms of TRS related to positive symptom
treatment targets. Connectivity and volumetric data may provide
further insight into the neurobiological mechanisms of TRS but are
not considered here because they are less likely to be relevant to
the development of new pharmacologic treatments.
NEUROBIOLOGY OF TRS
TRS may develop via one of several neurobiological pathways.
Several lines of evidence point to dopamine and glutamate
dysfunction in the development of TRS, although there is some
evidence that serotonin pathway dysfunction may also play a
role.8,26 One theory of TRS has been the dopamine supersensitivity
psychosis (DSP) hypothesis. This hypothesis, explaining TRS in
patients who were responsive to antipsychotic treatment at illness
onset, posits that continuous blockade of dopamine receptors by
antipsychotic medications leads to dopamine supersensitivity,
causing TRS.27,28 However, the DSP hypothesis is not universally
accepted, and clinical data do not consistently support it. This
review considers the evidence for and against the DSP hypothesis
and presents several other potential pathways and neurobiologi-
cal mechanisms that may lead to TRS.
DOPAMINE SUPERSENSITIVITY HYPOTHESIS
The DSP hypothesis was first proposed by Chouinard et al. in
1978,27 and subsequent work has acknowledged this hypothesis
as a potential etiology for some cases of TRS. The main known
Table 1. Comparison of treatment-resistant schizophrenia vs pseudo-resistance.8,11
TRS Pseudo-resistance
Cause: pharmacodynamic factors Cause: clinical or pharmacokinetic factors
● Adequate dose and duration of antipsychotic treatment ● Incorrect diagnosis
● Associated with early age of onset and long duration of illness ● Inadequate dose or duration of antipsychotic treatment
● Biological differences from treatment-responsive schizophrenia ● Insufficient plasma levels of antipsychotic medication
● Poor treatment compliance or adherence
● Adverse events or comorbid medical conditions masking response
● Substance use triggering psychosis
TRS treatment-resistant schizophrenia
ECT-resistant TRS
Treatment responsive Inadequate treatmentresponse
Clozapine-resistant TRS
Trial of ECT
Possible TRS
Treatment responsive
Treatment resistant
Treatment resistant
Confirmed TRS
with documented adherence
Treatment responsive Trial of clozapine*
Treatment responsive
Onset of schizophrenia symptoms
Trial of ECT
Fig. 1 Clinical path to confirmation of TRS. AP antipsychotic, ECT electroconvulsive therapy, TRS treatment-resistant schizophrenia. *If a trial
of clozapine was not previously completed.
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mechanism of action for antipsychotic medication is dopamine D2
receptor (DRD2) blockade.29–31 The dopamine supersensitivity
theory proposes that continuous blockade of DRD2 results in
dopaminergic changes that lead to breakthrough symptoms that
are no longer effectively treated by the initial dose of
antipsychotic medication.27,28,32–35 This chain of events is pro-
posed to lead to the need for increasing doses of antipsychotic
drugs to control symptoms, and rapid relapse during withdrawal
or dose reduction of an antipsychotic medication, or as tolerance
develops to previously therapeutic doses of antipsychotic
medication with continuous treatment.36
The dopaminergic changes following continuous receptor
blockade with an antipsychotic medication are proposed to
involve increases in DRD2 receptor density (Fig. 2a).33,37 In turn,
increases in antipsychotic medication doses to control break-
through symptoms are thought to lead to further increases in
DRD2 density, resulting in increased dopamine supersensitivity,
and consequently, the reemergence of symptoms.33,37 This implies
that TRS is related to duration of antipsychotic treatment; however,
positive symptoms of schizophrenia decrease with age and do not
increase as the DSP hypothesis implies.38 The emergence of tardive
dyskinesia is also proposed as a clinical characteristic reflecting
Fig. 2 Dopaminergic pathways to treatment resistance. (a) Dopamine supersensitivity and (b) dopaminergic subtypes.
S.G. Potkin et al.
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dopamine supersensitivity,33 although tardive dyskinesia is not
typically considered a feature of treatment resistance.1 The
dopamine supersensitivity hypothesis has generally focused on
DRD2 receptor changes but could also involve presynaptic
changes,39 albeit these do not seem to be marked with second-
generation antipsychotics.40
A survey from Suzuki et al. found that 70% of patients with TRS
showed one or more clinical characteristic consistent with the DSP
hypothesis. However, the criteria for DSP used in this study
included presence of either tardive dyskinesia or rebound
psychosis,32 and reliance on medical records rather than
systematic research assessments introduces uncertainty into the
classification of antipsychotic treatment and clinical status results.
Similarly, an observational study testing the effectiveness of
risperidone long-acting injection in patients with TRS found that
61 of 94 patients (65%) also had clinical characteristics proposed
to be due to DSP; although again, the presence of tardive
dyskinesia was sufficient for a designation of DSP.41 In patients
with TRS and proposed DSP, risperidone long-acting injection
improved scores on the Brief Psychiatric Rating Scale by ≥20%, a
significantly greater improvement than seen in patients with TRS
but without proposed DSP.41 This finding suggests that patients
meeting criteria for both DSP and TRS may be better treatment
responders than patients meeting criteria for TRS but not DSP
when the delivery method of antipsychotic medication promotes
stable blood levels within an optimal therapeutic window.41
However, it is important to note that identification of DSP is only
possible if a patient previously responded to antipsychotic
treatment, indicating that only patients who developed TRS after
initial response to antipsychotics fall into this category.33 A further
caveat to the survey and the long-acting injectable study41 is that,
in both studies, patients could be classified as having DSP if they
displayed tardive dyskinesia without showing breakthrough
positive symptoms. Although tardive dyskinesia is related to dose
and duration of antipsychotic treatment, it is not equivalent to
treatment resistance and is generally not considered a required
diagnostic feature of TRS.32,41,42
One prediction of the dopamine supersensitivity hypothesis is
that patients who have received prolonged antipsychotic treatment
(i.e., who would be anticipated to have developed supersensitivity)
will relapse rapidly on antipsychotic withdrawal. However, relapse
profiles, as well as clinical characteristics, are generally similar in
patients with longer and shorter treatment durations.43 From a
clinical perspective, relapse despite full adherence after achieving
remission does occur, as can best be seen in relapses on long-
acting injectable antipsychotic medications used after oral anti-
psychotic stabilization.44 Approximately 18% of patients receiving
long-acting injectable antipsychotic medications (for which
adherence is ensured) relapse within 1 year,45,46 although it is
difficult to determine whether these patients were truly in
remission at baseline. The results of these studies examining
relapse of patients on long-acting injectable antipsychotic
medications are not supportive of the dopamine supersensitivity
hypothesis.
If DRD2 receptors are upregulated or otherwise supersensitive
because of long-term antipsychotic treatment, in line with the DSP
hypothesis, and if medication is abruptly withdrawn, high levels of
unblocked receptors may interact with endogenous dopamine to
rapidly increase psychosis. In contrast, if medication is gradually
withdrawn, DRD2 receptors could downregulate in advance of
complete removal of blockade, allowing the supersensitivity to
resolve. Hence, a prediction of the DSP hypothesis is that relapse
rates should be higher in patients who abruptly, rather than
gradually, withdraw from antipsychotic treatment. However, a
meta-analysis failed to find differences in relapse rates between
patients gradually or abruptly discontinuing antipsychotic medi-
cations.47 A recent study found that relapse rates were higher in
patients withdrawn from long-acting injectable paliperidone
palmitate (i.e., gradual withdrawal of antipsychotic medication)
and switched to placebo treatment compared with those receiving
maintenance treatment (hazard ratio, 3.60; 95% confidence
interval, 2.45–5.48).45 However, there was no significant difference
in relapse symptom severity between patients who experienced a
relapse while continuing treatment and those who relapsed upon
medication withdrawal, indicating that relapse upon withdrawal is
not clinically different from illness recurrence; abrupt return of
psychotic symptoms was also common in both groups.45
If upregulation of DRD2 receptors occurs with prolonged use of
antipsychotic medication, then patients would be expected to
demonstrate tolerance, necessitating higher doses over time. A
recent study found that the dosage of antipsychotic medication
necessary to treat a relapse of psychosis was significantly higher
than the dosage that had been necessary to treat first-episode
psychosis, lending support to the tolerance aspect of the DSP
hypothesis.48 However, there are other possible explanations for
the need for an increased dose: each episode of psychosis may be
evidence of disease progression, necessitating higher doses of
medication to achieve symptom relief.48 A recent study found that
patients took longer to respond to treatment after a relapse of
psychosis than for a first episode, even after adjustment for
antipsychotic medication dose.10 Duration of illness (>10 years vs
>5 years) was a significant predictor of relapse, even with the
ensured adherence of treatment with a long-acting injectable
antipsychotic medication, suggesting that disease progression of
schizophrenia affects response to treatment.46 Finally, DRD2
receptor upregulation occurs on a much shorter timescale, on
the order of weeks rather than years,27 making DSP an unlikely
candidate for the mechanism of treatment resistance in the study
by Alphs and colleagues.46
Studies in a rat model of schizophrenia have investigated the
effects of antipsychotic treatment on the dopamine system. Loss
of gamma-aminobutyric acid (GABA) interneurons during adoles-
cence in the methylazoxymethanol acetate (MAM) model led to
hyperactivity of midbrain dopaminergic neurons, consistent with
findings in patients with schizophrenia.49 Treatment with a
positive allosteric modulator of the α5 subunit of GABA-A
receptor, which restores some of the inhibitory capabilities to
brain regions that regulate dopaminergic neurons, ameliorated
schizophrenia-like symptoms in MAM-treated rats.50 However,
pretreating MAM-treated rats with haloperidol, an antipsychotic
DRD2 antagonist, for 3 weeks and then discontinuing it before
initiation of the GABA modulator blocked these therapeutic effects
of the GABA modulator.35 This finding suggests that even
temporary dopamine receptor blockade can alter the effects of
future treatments on the dopamine system, even when they do
not directly act on dopamine receptors.
As previously mentioned, an important caveat to the DSP
hypothesis is that it accounts only for cases of TRS that emerge
after an initially successful treatment with an antipsychotic
medication.32,36 Thus, it is likely that TRS apparent at the first
episode of schizophrenia is neurobiologically distinct from TRS
that develops over time.10
HYPERDOPAMINERGIC AND NORMODOPAMINERGIC
SUBTYPES HYPOTHESIS
Increased striatal dopamine synthesis and release capacity in vivo
are linked to psychotic relapse and the development of the first
psychotic episode,51–53 with large effect size elevations on meta-
analysis.54 However, it has been proposed that not all patients
with schizophrenia display striatal hyperdopaminergic activity and
that some patients with TRS demonstrate normal dopamine
regulation or even hypodopaminergic activity (Fig. 2b).25 Evidence
for this hypothesis comes from positron emission tomography
studies showing that dopamine synthesis capacity in the striatum
is significantly higher in vivo in patients with treatment-responsive
S.G. Potkin et al.
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schizophrenia relative to patients with TRS, who, in turn, have a
dopamine synthesis capacity similar to healthy controls.24,53,55
Dopamine synthesis capacity in the striatum has been shown to
be lower in patients with TRS who are clozapine-responsive
compared with healthy controls or patients without TRS.56 An
important issue is whether these differences between treatment-
responsive and treatment-resistant patients are present from
illness onset or not. A recent study in first-episode patients found
evidence that this was the case (i.e., differences present from
illness onset), with elevated striatal dopamine synthesis capacity in
first-episode patients who went on to respond to antipsychotic
treatment, but unaltered dopamine synthesis capacity in first-
episode patients who did not respond to antipsychotic treat-
ment.53 This finding suggests that there may be dopaminergic
subtypes of schizophrenia of treatment resistance from illness
onset. Notwithstanding these lines of in vivo evidence,53,56 one
important issue is whether dopamine differences between TRS
and responsive patients are categorical, as proposed by the
subtype hypothesis, or whether they are a matter of degree, as
suggested by correlations between dopamine synthesis capacity
and symptom change with antipsychotic treatment.53 Further
cross-sectional and longitudinal studies are needed to address this
issue (see research roadmap below).
GENETIC VARIANTS THAT MAY CONTRIBUTE TO
SCHIZOPHRENIA OR TRS
Possible associations between several dopamine-related poly-
morphisms and TRS have been investigated. A combination of
dopamine transporter (DAT-40 base pair variable number of
tandem repeat [DAT-VNTR]) and serotonin transporter (SERT-VNTR
intron 2 [SERT-in2]) polymorphisms has been associated with
TRS.57 A study of two single-nucleotide polymorphisms (SNPs) in
the dopamine-degrading enzyme catechol-O-methyltransferase
(COMT) demonstrated that a higher-activity haplotype was
protective against TRS in women but not men.58 Genetic
polymorphisms in DRD2 may also affect a patient’s risk of
developing DSP TRS or the likelihood that a patient will respond
to non-clozapine antipsychotic medications.36,59 However, another
study showed no association between TRS and SNPs in DRD1,
DRD2, DRD3, or COMT.60 A study of copy number variations (CNVs)
in a Japanese population observed that patients with clinically
significant de novo CNVs were more likely to have TRS, perhaps
indicating genetic instability.61 A genome-wide association screen
in patients with schizophrenia found an association between
variation in genes related to targets of some antipsychotic
medications and TRS, as defined by a lack of response to standard
treatments.62 The gene sets and individual genes most associated
with antipsychotic treatment targets included N-methyl-D-
aspartate (NDMA)-relevant genes and GRIN2a, in particular.62
Singleton deleterious variants found in genes targeted by
antipsychotic medications were enriched in individuals with TRS,
as defined by the presence of a clozapine prescription.62
Notably, these genes were not all related to dopaminergic
receptors, indicating that development of TRS may occur through
multiple pathways.62 A study comparing gene expression among
patients with TRS, patients with treatment-responsive schizophre-
nia, and healthy controls found no difference between the groups
with schizophrenia in the expression of 13 candidate genes,
including COMT.63 Although there are inconsistencies and
variability among the results of some of these highlighted studies,
several candidates for the biological mechanisms or subtypes of
TRS require further research. Additional studies are needed to
further characterize these candidate biological mechanisms and to
identify new treatment targets.
GLUTAMATE HYPOTHESIS
Although dopamine dysregulation clearly contributes to the
symptoms of schizophrenia in many patients, the failure of
antipsychotic dopamine blockade to control symptoms in some
patients implies that other neurotransmitters likely play a role in the
etiology of TRS, as suggested by the subtype hypothesis.64 The most
prominent hypothesis for the involvement of other neurotransmitter
systems in the neurobiology of schizophrenia is the glutamate
hypothesis, which suggests that dopamine hyperactivity is down-
stream of GABA and glutamate dysregulation.26 According to the
glutamate hypothesis, NMDA receptor dysfunction on GABA
interneurons results in disinhibition of cortical or hippocampal
glutamate neurons projecting to the basal ganglia. This hyperactiva-
tion of glutamate neurons, in turn, stimulates activity of dopami-
nergic projections from the midbrain to the striatum, resulting in the
positive symptoms of schizophrenia.64–66 This theory is supported
by observations that patients with schizophrenia show an exacer-
bation of positive symptoms after administration of phencyclidine
(PCP), an NMDA receptor antagonist, and that PCP mimics the
positive effects of schizophrenia in healthy volunteers.67,68
There is evidence that abnormalities in glutamate regulation
may specifically play a role in TRS.24,25,69 Neuroimaging studies
have measured brain glutamate levels in patients with schizo-
phrenia in comparison with healthy controls.24,70 Glutamate levels
in the anterior cingulate cortex were higher in patients with TRS
compared with healthy controls or patients with schizophrenia
who were treatment responsive.24,70
Another neuroimaging study measured levels of glutamate as
well as glutamate+ glutamine (Glx) in several brain regions in
patients with TRS treated with clozapine in comparison with patients
who were first-line antipsychotic treatment responders, patients
with TRS unresponsive to clozapine, and healthy controls.69 Glx is
the precursor for glutamate.69 Glx but not glutamate levels were
higher in the putamen of patients with clozapine-responsive TRS
than in first-line responders or patients with clozapine-
nonresponsive TRS.69 This difference between groups could
potentially be related to differences in the activity of the enzyme
that converts Glx to glutamate or to a problem with Glx reuptake,
resulting in excess Glx.69 Although the precise mechanisms of action
of clozapine are unknown, this work may support evidence for a
contribution of a glutamate-related mechanism of action.69
Indirect evidence for glutamate’s role in clozapine-responsive TRS
is supported by studies examining the effect of clozapine on the
glutamatergic system.71 Clozapine has high affinity for DRD4, and in
a rat model, blockade of DRD4 upregulated α-amino-3-hydroxy-5-
methyl-4-isoxazoleproprionic acid (AMPA) receptors, improving
glutamatergic transmission.72,73 Clozapine also increases release of
L-glutamate and D-serine in rat frontal cortex, which can result in
upregulation of NMDA receptors.71 If NMDA receptors are hypofunc-
tional in TRS, it is possible that clozapine could partially compensate
for this dysfunction.73 In a study examining D- and L-serine levels in
patients with TRS before and after clozapine treatment, patients with
TRS had significantly lower D-serine levels before clozapine
treatment than did healthy controls, a difference that disappeared
after clozapine treatment.74 Similarly, the D-/L-serine ratio was
significantly lower in patients with TRS before clozapine treatment
but not significantly different from healthy controls after clozapine
treatment, providing further support to the hypothesis that
clozapine’s mechanism of action may be related to regulation of a
dysfunctional glutamatergic pathway.74 Glycine opens NMDA
channels and thus could counteract a hypoglutamatergic state;
however, in a double-blind study of patients with TRS taking 30 g of
glycine adjunctive to optimal doses of clozapine, patients taking only
clozapine demonstrated significant improvement in positive symp-
toms.75 The multicenter CONSIST study also found no beneficial
effects of high-dose glycine or glutamatergic agents on negative or
cognitive schizophrenia symptoms.76 Additionally, data from phase 3
S.G. Potkin et al.
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clinical trials of adjunctive bitopertin, a glycine reuptake inhibitor,
showed no statistical difference from placebo in positive or negative
symptoms.77,78 Nevertheless, these studies were not specifically in
TRS, highlighting that it would be useful to test this mechanism in
this patient population. Other drug targets and mechanisms in the
glutamate pathway should also be explored.
In patients with TRS not responding to clozapine, concomitant
use of glutamate release inhibitors such as lamotrigine73 or
topiramate79 may increase treatment response; however, the quality
of studies has been mixed, and the efficacy of various pharmaco-
logical augmentation strategies in patients with clozapine-resistant
schizophrenia remains unclear.21 Further high-quality randomized
clinical trials are needed to establish the effectiveness of these
glutamatergic augmentation strategies and to identify patient
subgroups that have a higher likelihood of responding to specific
pharmacological combination or augmentation strategies.21
INFLAMMATION AND OXIDATIVE STRESS
Neuroinflammation early in life followed by chronic overactivation
has been hypothesized to contribute to the etiology of schizo-
phrenia; it is possible that high levels of inflammation play a role
in treatment resistance as well.80,81 Specific immune-inflammatory
cytokine profiles have been associated with both treatment-
responsive schizophrenia and TRS82; levels of these biomarkers
can be present from illness onset and thus do not represent a
downstream effect of psychosis.81
Oxidative stress, as measured by lipid peroxidation, was
elevated in patients with TRS compared with patients with
treatment-responsive schizophrenia and healthy controls.83 It is
possible that oxidative stress–related neuronal damage also
contributes to TRS. Individuals with gene deletions in the
antioxidant glutathione S-transferase family may have an
increased risk of TRS compared with healthy controls.84 However,
this study was limited by the lack of a treatment-responsive
schizophrenia control group,84 and more research is needed to
determine the role of oxidative stress in TRS.
SEROTONIN
Serotonin plays a complex role in modification of dopamine
neurotransmission and is thought to contribute to the neuro-
biology of schizophrenia.85,86 There is evidence of lower levels of
serotonin 2A receptors (and higher levels of serotonin 1A
receptors) postmortem with moderate to large effect sizes in
schizophrenia in general, although imaging findings are incon-
sistent and treatment resistance has received little attention.87
Notwithstanding this, polymorphisms in serotonin receptors
have been associated with response to clozapine.88 Modulators
of serotonin have shown some efficacy in improving negative
symptoms as augmentation therapy in combination with
antipsychotics medications,89 but higher-quality studies are
needed to confirm these findings.21
ELECTROCONVULSIVE THERAPY
Concomitant use of clozapine and ECT may also be valuable as an
augmentation strategy in patients who do not respond to
clozapine alone, raising additional questions about the underlying
mechanisms of treatment resistance.22,23 A prospective study
found that half of patients with TRS not responding to clozapine
treatment alone demonstrated ≥40% improvement on the Brief
Psychiatric Rating Scale psychotic symptom subscale when
concomitantly treated with ECT.23 A meta-analysis examining
the efficacy of ECT augmentation confirmed that it is both
effective and safe in patients with clozapine-resistant TRS.22 The
efficacy of this strategy may provide insight into the mechanisms
of TRS and requires further study.
LIMITATIONS OF EVIDENCE FOR THE POSSIBLE MECHANISMS
OF TRS
The evidence considered in our review is limited by several factors,
including variation in the criteria used to define TRS, small sample
sizes of many studies, and the fact that few studies differentiate
between initial and later onset TRS.1 Consequently, there is not a
universally accepted or definitive mechanism for TRS. There is also
heterogeneity among patients with schizophrenia, including those
with TRS, in their clinical characteristics, response to treatment, and
underlying neurobiology.90 It is likely that there are several distinct
subgroups and neurobiological profiles of patients with TRS; further
work is needed to differentiate these subgroups, define their
characteristics and possible biomarkers, and study their individual
response patterns to treatment. Among patients with TRS, there are
also important clinical differences, most strikingly between patients
who respond to clozapine and those who do not. A key future
direction is to develop biomarkers to predict TRS early in the course
of illness to identify the neurobiological mechanisms underlying TRS
and guide treatment selection. Candidate serological biomarkers for
TRS associated with schizophrenia treatment response could include
decreased brain-derived neurotrophic factor (BDNF) and levels of
soluble interleukin (IL)–2 receptor (sIL-2R), IL-6, and IL-1 receptor
antagonist (IL-1RA).81,91,92 Other candidate biomarkers could include
normal striatal dopamine synthesis despite a schizophrenia
diagnosis and resting state striatal connectivity.24,93,94 Biomarkers
that predict treatment resistance or clozapine response will likely be
difficult to implement if they are very expensive or difficult to obtain
(e.g., lumbar puncture, neuroimaging), but these factors should be
weighed against the high cost of TRS.95 It is likely that a combination
of biomarkers and patient clinical information will improve
prediction of TRS and medication response.95,96
RESEARCH ROADMAP
The neurobiological diversity of schizophrenia as exemplified by TRS
suggests that clinical trial strategies need to be informed by both the
biology and diverse clinical presentation of the individual patient.25
The cross-sectional diversity of the neurobiology of TRS, coupled with
the clinical evidence for TRS being present from illness onset in some
patients and developing over time in others, indicates that there
need to be biological studies of phase-specific underlying mechan-
isms of TRS. Such studies include examining TRS in first-episode
psychosis, TRS in established schizophrenia and TRS emerging in
older age patients, and longitudinal studies that investigate
biological changes in the dopamine and other systems during
the course of illness. Another important consideration is whether the
biological changes associated with TRS are categorically different
from those in treatment-responsive schizophrenia or are on a
continuum with those seen in treatment-responsive patients.97 Thus,
a goal of research priorities for TRS should be to differentiate the
underlying neurobiological factors among patients with TRS from
those in treatment-responsive patients (Fig. 3).
Research roadmap
Goal: Determine the neurobiolo  y underlyin    TRS
Fig. 3 Clinical research priorities for TRS. TRS treatment-resistant
schizophrenia.
S.G. Potkin et al.
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CONCLUSIONS
The roadmap for understanding the pathophysiology of TRS and
improving outcomes for patients should focus on developing
methods for categorizing this patient group based on features
such as the stage of illness when TRS emerges, clinical
phenomenology, the response to dopamine antagonists and
clozapine, and biomarkers. Two main dopaminergic theories have
been proposed to explain TRS. The first proposes that TRS is
characterized by normal dopamine function, while glutamate or
other pathways contribute to the distinct neurobiology of TRS. The
other proposes that dopamine supersensitivity leads to the
development of TRS over time. It is important to recognize that
these two models are not mutually exclusive. Moreover, they may
explain different presentations of TRS, with the normal dopamine
hypothesis explaining treatment resistance from illness onset, and
the dopamine supersensitivity hypothesis explaining the devel-
opment of treatment resistance in some patients (Table 2).
There are still many gaps in the understanding of the
pathophysiology and pathways leading to the development of
TRS. Closing these gaps may lead to improved treatment options
for patients with TRS. Several candidates for the biological
mechanism and/or subtypes of TRS have been identified.
However, none have been widely replicated to date, and more
research is needed to test them in different patient populations
and different phases of illness. The likely heterogeneity of
pathways into and mechanisms sustaining TRS within this
population further complicates research. Given the major health
burden of TRS for patients and families and to make significant
progress toward these goals, it would be useful if organizations
such as the National Institute of Mental Health (NIMH) in the
United States and similar funding bodies around the world placed
more emphasis and funding on research into the underlying
biology of TRS.
METHODS: SEARCH STRATEGY AND SELECTION CRITERIA
A selective PubMed search was performed for the dates January 1,
2007, to September 26, 2018, using the following terms:
“schizophrenia” AND “drug resistance” OR “treatment refractory”
OR “treatment failure” OR “treatment refractoriness,” “clozapine,”
“treatment resistant schizophrenia,” “biology of treatment resis-
tant schizophrenia,” “biological mechanisms of treatment resistant
schizophrenia,” “pathophysiology of treatment resistant schizo-
phrenia,” “pathways to treatment resistant schizophrenia,” “ima-
ging” AND “treatment resistant schizophrenia,” “PET imaging”
AND “treatment resistant schizophrenia,” and “spectroscopy” AND
“treatment resistant schizophrenia.” Additional searches were
conducted based on reviews of the articles identified in the initial
PubMed search. Articles included in this narrative review were
limited to those in English-language, peer-reviewed journals.
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